A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

BACKGROUND: We previously reported that administration of bortezomib (BTZ) after 4 days of G-CSF significantly augments mobilization in mice. We hypothesized that administration of BTZ at peak G-CSF mobilization in patients with multiple myeloma (MM) would be safe, augment mobilization, and have an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lymphoma Myeloma Leuk
Main Authors: Ghobadi, Armin, Fiala, Mark A, Rettig, Michael, Schroeder, Mark, Uy, Geoffrey L., Stockerl-Goldstein, Keith, Westervelt, Peter, Vij, Ravi, DiPersio, John F
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497838/
https://ncbi.nlm.nih.gov/pubmed/31358485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2019.04.017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados